Overexpression of vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate

Phase I Study of Subconjunctival Ranibizumab in Patients With Primary Pterygium Undergoing Pterygium Surgery

(2010) Anat Galor et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

The Effect of Subconjunctival Ranibizumab on Primary Pterygium: A Pilot Study

(2010) Achilleas Mandalos et al.   CORNEA

Effect of Pterygia on Refractive Indices, Corneal Topography, and Ocular Aberrations

(2010) Koray Gumus et al.   CORNEA

Effect of Subconjunctival Bevacizumab on Primary Pterygium

(2009) Christopher C Teng et al.   CORNEA

Efficacy of Topical Bevacizumab for Inhibiting Growth of Impending Recurrent Pterygium

(2009) Mohammad Reza Fallah et al.   CURRENT EYE RESEARCH

Pathogenetic mechanisms and treatment options for ophthalmic pterygium: Trends and perspectives (Review)

(2009) Detorakis   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Preliminary Results of Subconjunctival Bevacizumab in Primary Pterygium Excision

(2009) Mohammad Reza Razeghinejad et al.   OPHTHALMIC RESEARCH

Subconjunctival Bevacizumab Injection for Corneal Neovascularization in Recurrent Pterygium

(2008) Irit Bahar et al.   CURRENT EYE RESEARCH